Cerebral blood flow in patients with fabry disease as measured by doppler sonography is not different from that in healthy individuals and is unaffected by treatment

Journal of Ultrasound in Medicine

Volumn 31, Issue 3, 2012, Pages 463-468

  Üçeyler, Nurcan ^a,b,c   He, Lan ^a,b,c   Kahn, Ann Kathrin ^a   Breunig, Frank ^a,b,c,d   Müllges, Wolfgang ^a   Sommer, Claudia ^a,b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Department of Medicine Divisions of Cardiology and Nephrology Fabry Center for Interdisciplinary Therapy   (Germany)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d KfH Center for Dialysis and Kidney Transplantation   (Germany)

Author keywords

Enzyme replacement therapy; Extracranial Doppler sonography; Fabry disease; Transcranial Doppler sonography

Indexed keywords

BLOOD; BLOOD VESSELS; ENZYMES; HEMODYNAMICS; PATIENT TREATMENT; ULTRASONIC IMAGING; ULTRASONOGRAPHY;

CASE-CONTROL STUDY; CEREBRAL BLOOD FLOW; DOPPLER SONOGRAPHY; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HEALTHY INDIVIDUALS; IMPAIRED RENAL FUNCTION; TRANSCRANIAL DOPPLER SONOGRAPHY;

DISEASE CONTROL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BRAIN CIRCULATION; CASE CONTROL STUDY; DOPPLER ECHOGRAPHY; ECHOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CEREBROVASCULAR CIRCULATION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84857864912     PISSN: 02784297     EISSN: None     Source Type: Journal    
DOI: 10.7863/jum.2012.31.3.463     Document Type: Article

References (24)

1. Schiffmann R Fabry disease Pharmacol Ther 2009; 122:65-77.
2. Barbey F, Brakch N, Linhart A, et al Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 2006; 26:839-844. (Pubitemid 43732160)
3. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138:338-346 (Pubitemid 36205932)
4. Feldt-Rasmussen U. Fabry disease and early stroke. Stroke Res Treat 2011; 2011:615218.
5. Fellgiebel A, Müller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005; 65:600-602. (Pubitemid 41170723)
6. Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiff mann R White matter lesions in Fabry disease occur in "prior" selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003; 62:231-240. (Pubitemid 38091711)
7. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009; 40:788-794
8. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease J Neurol 2004; 251:564-570. (Pubitemid 38680299)
9. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33:525-531. (Pubitemid 34123400)
10. Üçeyler N, He L, Schönfeld D, et al. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J Peripher Nerve Syst 2011; 16:304-314
11. Newell DW, Aaslid R Transcranial Doppler. New York: Raven Press; 1992.
12. Hennerici M, Rautenberg W, Schwartz A Transcranial Doppler ultrasound for the assessment of intracranial arterial flow velocity, part 2: evaluation of intracranial arterial disease Surg Neurol 1987; 27:523-532. (Pubitemid 17073856)
13. Widder B, Görtler M.Doppler und Duplex Sonographie der Hirnversorgen-den Arterien. Berlin, Germany: Springer-Verlag; 2004.
14. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant2009; 24:2102-2111.
15. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18:2609-261
16. Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2007; 2:e598.
17. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hol-lak CE. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 2010; 99:99-108.
18. Barbey F, Brakch N, Linhart A, et al Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease Acta Paediatr Suppl 2006; 95:63-68. (Pubitemid 43739098)
19. Kalliokoski RJ, Kalliokoski KK, Penttinen M, et al. Structural and functional changes in peripheral vasculature of Fabry "patients.J Inherit Metab Dis 2006; 29:660-666. (Pubitemid 44390429)
20. Moore DF, Scott LT, Gladwin MT, et al Regional cerebral hyperperfu-sion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001; 104:1506-1512. (Pubitemid 32917343)
21. Fellgiebel A, Keller I, Martus P, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 2011; 31:294-299.
22. Garzuly F, Marodi L, Erdos M, et al. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain2005; 128:2078-2083. (Pubitemid 41253275)
23. Gupta S, Ries M, Kotsopoulos S, Schiffmann R The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women Medicine (Baltimore) 2005; 84:261-268. (Pubitemid 41368479)
24. Jardim L, Vedolin L, Schwartz IV, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 2004; 27:229-240. (Pubitemid 38756339)